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ABSTRACT 
Orexin-A and orexin-B are hypothalamic neuropeptides that play critical roles in the 
maintenance of wakefulness. Intracerebroventricular (ICV) administration of orexin-A 
has been shown to promote wakefulness and suppress both rapid eye movement 
(REM) sleep and non-REM (NREM) sleep through the orexin receptor-1 (OX1R) and 
orexin receptor-2 (OX2R). Here, we elucidated the differential roles of orexin 
receptors in the regulation of sleep and wakefulness by comparing the effects of ICV 
orexin-A administration in wild-type, OX1R-/- and OX2R-/- mice. The effects of orexin-
A on wakefulness and NREM sleep were significantly attenuated in both knockout 
mice as compared to wild-type mice, with substantially larger attenuation in OX2R-/- 
mice than in OX1R-/- mice. These results suggest that although the OX2R-mediated 
pathway has a pivotal role in the promotion of wakefulness, OX1R also plays 
additional roles in promoting arousal. In contrast, suppression of REM sleep by 
orexin-A administration was slightly and similarly attenuated in both OX1R -/- and 
OX2R -/- mice, suggesting a comparable contribution of the two receptors to REM 
sleep suppression. Histological studies demonstrated differential distributions of each 
receptor subtype in distinct neuronal populations with specific neurotransmitter 
identities in brainstem cholinergic/monoaminergic neurons.  In the laterodorsal 
tegmental and pedunculopontine tegmental nuclei especially, cholinergic neurons 
exclusively expressed OX1R mRNA, but OX2R mRNA was expressed mainly in 
GABAergic putative interneurons. Thus, each orexin receptor subtype plays 
differential roles in gating NREM and REM sleep, through distinct neuronal pathways. 
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INTRODUCTION 
Neurons expressing orexins (hypocretins) are distributed within the perifornical 
lateral hypothalamus and send projections throughout the brain and spinal cord, with 
particularly dense innervations to nuclei containing monoaminergic and cholinergic 
neurons constituting the ascending activating system in the brainstem (de Lecea et al., 
1998; Sakurai et al., 1998; Peyron et al., 1998; Chemelli et al., 1999; Date et al., 1999; 
Nambu et al., 1999; van den Pol, 1999). Two subtypes of orexin receptors were also 
found to be abundantly expressed in these monoaminergic/cholinergic nuclei with 
distinct distributions (Trivedi et al., 1998; Marcus et al., 2001). ICV injection of 
orexin in mice and rats has been shown to increase wakefulness potently and suppress 
both non-REM (NREM) and REM sleep (Hagan et al., 1999; Piper et al., 2000), at 
least partly by acting on these monoaminergic/cholinergic neurons. Loss of orexin 
neurons is associated with narcolepsy in the human, a condition characterized by 
excessive daytime sleepiness, sleep-onset REM periods, and cataplexy (sudden 
bilateral skeletal muscle weakness without impairment of consciousness) (Nishino et 
al., 2000; Peyron et al., 2000; Thannickal et al., 2000), highlighting a critical role of 
orexins in the maintenance of wakefulness. 
Mice with targeted deletion of the prepro-orexin gene (orexin-/- mice) display a 
phenotype strikingly similar to narcolepsy: brief, abrupt behavioral arrests with 
muscle atonia (i.e., potentially cataplexy), fragmented wakefulness, and direct 
transitions from wakefulness to REM sleep (Chemelli et al., 1999). In addition, 
functionally null mutations in the OX2R gene were found in familial narcoleptic dogs 
(Lin et al., 1999). Consistently, OX2R-/- mice are also narcoleptic, although their 
phenotype is significantly milder than that of orexin-/- mice (Willie et al., 2003). In 
contrast, OX1R-/- mice do not exhibit any overt behavioral abnormalities (Sakurai, 
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2007; Hondo et al., 2010). These observations suggest that the OX2R-mediated 
pathway has a pivotal role, although OX1R has an additional role in the regulation of 
sleep/wake states. 
The discovery of a causal link between loss of orexin signaling and narcolepsy 
has brought about the possibility of novel therapies for the disorder. Indeed, we 
previously demonstrated that acute ICV administration of orexin-A maintained 
wakefulness, suppressed sleep, and inhibited cataplectic attacks in a murine model of 
narcolepsy (Mieda et al., 2004). Thus, orexin receptor agonists would be of potential 
value for treating narcolepsy, as well as other conditions of excessive daytime 
sleepiness in humans. Likewise, dual orexin receptor antagonists, which antagonize 
both receptors with similar affinity, have been shown to have potential as new 
medications for the treatment of insomnia (Brisbare-Roch et al., 2007), although 
single selective OX2R antagonists have been reported to be more effective for sleep 
promotion than dual antagonists in rats (Dugovic et al., 2009). Therefore, analysis of 
the physiological roles of each receptor in sleep/wakefulness regulation is particularly 
important to understand the mechanisms of the action of these drugs targeted to 
orexin receptors. 
In the present study, we compared the effects of ICV orexin-A administration 
on sleep/wakefulness states in wild-type mice, OX1R-/- mice, and OX2R-/- mice. In 
addition, we histologically determined the subtypes of orexin receptors expressed in 
neurons implicated in sleep/wakefulness regulation. 
 
MATERIALS AND METHODS 
Animals 
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Fourteen to twenty week-old male mice from four genotypes (wild-type, OX1R-/-, 
OX2R-/-, and OX1R-/-;OX2R-/- mice, N5-N6 backcross to C57BL/6J, generated by 
crosses between homozygous mice) were used (Willie et al., 2003; Sakurai, 2007). All 
experimental procedures involving animals were approved by the appropriate 
institutional animal care and use committees of the University of Texas Southwestern 
Medical Center at Dallas or Kanazawa University. All efforts were made to minimize 
animal suffering and discomfort and to reduce the number of animals used. 
 
EEG/EMG Recordings Following Intracerebroventricular Administration of 
Orexin-A 
Mice were anesthetized and implanted with an EEG/EMG implant and a guide 
cannula as previously described (Mieda et al., 2004). All animals were allowed to 
recover for at least 10 days prior to experiments; mice utilized for further study had 
regained their preoperative body weight and exhibited no obvious sign of infection. 
Prior to the sleep/wakefulness evaluation, mice were habituated to the experimental 
procedure by gentle restraint once a day for two days prior to the experiment. 
 Each mouse was administered various doses of synthetic orexin-A (0.3, 1, and 
3 nmol in 1 µl of sterile artificial cerebrospinal fluid per mouse ICV, Glaxo 
SmithKline Pharmaceuticals) or vehicle at 3 h into the light phase [zeitgeber time 
(ZT) 3] using a randomized crossover design at an interval of 3-4 days (Mieda et al., 
2004). Mice were then returned to their home cages for immediate recording of 
EEG/EMG for the subsequent 8 h. Mice were treated with penicillin-G benzathine / 
penicillin-G procaine suspension (100,000 U/kg s.c.) after the surgery and each 
recording session. 
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EEG/EMG records were visually scored according to standard criteria of 
rodent sleep and further analyzed using custom software (Chemelli et al., 1999; Willie 
et al., 2003). Latencies to NREM sleep and REM sleep were defined as the intervals 
between the ICV administration and the initiation of the first episodes of NREM sleep 
and REM sleep, respectively, that continued for at least one epoch (i.e., 20 seconds).  
 
In Situ Hybridization 
Preparation of coronal brain sections and single in situ hybridization were performed 
according to procedures previously described (Mieda et al., 2006). For double in situ 
hybridization, each combination of two antisense riboprobes labeled with either 
fluorescein-UTP (for VMAT2, VAChT, or Gad1) or digoxygenin-UTP (for OX1R or 
OX2R) was hybridized to sections simultaneously. Following the chromogen reaction 
of the first color (blue) obtained with anti-digoxygenin-alkaline phosphatase (AP) Fab 
fragments, 5-bromo-4-chloro-3-indolyl phosphate (Roche) and nitroblue tetrazolium 
(Roche), sections were rinsed three times with TBS, treated twice with 0.1M glycine 
pH 2.2; 0.1% Tween 20 for 5 min, washed, and then incubated with anti-fluorescein-
alkaline phosphatase (AP) Fab fragments. For the chromogen reaction of the second 
color (orange), 5-bromo-4-chloro-3-indolyl phosphate (Roche) and 2-[4-iodophenyl]-
3-[4-nitrophenyl]-5- phenyl-tetrazolium chloride (Roche) were used. 
Antisense riboprobes were synthesized from plasmids containing rat OX1R 
(NM_013064, nucleotides 824-1813), rat OX2R (NM_013074, nucleotides 23-1439), 
rat VMAT2 (NM_013031, nucleotides 28-762), rat VAChT (NM_031663, nucleotides 
65-2587), and mouse Gad1 (NM_008077, nucleotides 281-821) cDNAs. 
 
Statistical Analysis 
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For the hourly distribution of vigilance states (Fig. 1), data collected from each strain 
of mice were analyzed by one-way repeated-measures ANOVA and Tukey post-hoc 
tests to detect significant dose effects. For dose responses of the time spent in each 
vigilance state and latencies to NREM and REM sleep (Fig. 2), data of every 
combination of two mouse strains were analyzed by two-way repeated-measures 
ANOVA to detect significant effects of dose and genotype, followed by post-hoc tests 
to detect significant effects of genotype within each dose. For cumulative time in 
NREM sleep and REM sleep in OX2R-/- mice (Fig. 3A, B), data of every combination 
of two doses were analyzed by two-way repeated-measures ANOVA to detect 
significant effects of dose. For percent of time spent in NREM or REM sleep within 4 
h following 1 or 3 nmol orexin-A administration relative to vehicle administration in 
OX2R-/- mice (Fig. 3C), data were analyzed by two-way repeated-measures ANOVA to 
detect significant effects of dose and vigilance states. For testing correlation between 
latencies to NREM sleep and REM sleep, Pearson’s correlation coefficients were 
calculated for OX1R-/- and OX2R-/- mice with data of 1 and 3 nmol orexin-A 
administration. Probability (p) values less than 0.05 were considered statistically 
significant. Only relevant information from the statistical analysis has been indicated 
in the text and figures. 
 
RESULTS 
Promotion of wakefulness and suppression of NREM sleep by ICV orexin-A 
administration 
In order to further elucidate the differential roles of orexin receptors in 
sleep/wakefulness regulation, we compared the wakefulness-promoting and sleep-
suppressing effects of ICV orexin-A administration in wild-type, OX1R-/-, OX2R-/-, and 
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OX1R-/-;OX2R-/- mice. Synthetic orexin-A (0.3, 1, and 3 nmol/mouse) or vehicle was 
administered into the lateral ventricle at 3 h into the light phase (ZT3), and EEG/EMG 
signals were recorded for the subsequent 8 h. The doses and route of administration 
chosen were comparable to those used previously to examine the effects of orexin-A 
on behavior and metabolism in rodents (Lubkin and Stricker-Krongrad, 1998; Hagan 
et al., 1999; Piper et al., 2000; Stricker-Krongrad et al., 2002). The specific action of 
orexin-A administration on orexin receptors was further confirmed by the lack of any 
effect when the neuropeptide was administered to OX1R-/-;OX2R-/- mice (Figs. 1D, H, 
2). 
As previously reported, orexin-A administration in wild-type mice increased 
wakefulness time in a dose-dependent manner (n = 8, p < 0.0001) accompanied by a 
decrease in NREM sleep time (n = 8, p < 0.0001) (Figs. 1A, 2A, B, D). These effects 
continued for 2 h after administration at all doses examined (Fig. 1A). 
In OX1R-/- mice, the effects of orexin-A administration on wakefulness and 
NREM sleep were slightly but significantly smaller than those in wild-type mice. The 
effect of the lowest dose of orexin-A (0.3 nmol) lasted for only 1 h in OX1R-/- mice 
(Fig. 1B). During the first 2 h after administration, orexin-A increased wakefulness 
time (n = 6, p < 0.0001) and suppressed NREM sleep time (n = 6, p < 0.0001) in a 
dose-dependent manner in OX1R-/- mice, but to a degree significantly less than that in 
wild-type mice (n = 8 and 6 for wild-type and OX1R-/- mice, respectively, p = 0.0078 
and 0.0082 for wakefulness and NREM sleep, respectively) (Fig. 2A, B). However, 
the latency to the first episode of NREM sleep after administration in OX1R-/- mice 
was not significantly different from that in wild-type mice (n = 8 and 6 for wild-type 
and OX1R-/- mice, respectively, p = 0.1229) (Fig. 2D). 
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In contrast, the effects of orexin-A administration in OX2R-/- mice were 
considerably attenuated as compared to those in both wild-type and OX1R-/- mice. 
Although all doses of orexin-A examined increased wakefulness in OX2R-/- mice in 
the first hour following administration (n = 6, p = 0.0002 for all three doses as 
compared to vehicle), these effects dissipated more rapidly when compared with wild-
type and OX1R-/- mice (Fig. 1C). Accordingly, the dose response curve of 2 h 
wakefulness in OX2R-/- mice was below those of both wild-type (n = 8 and 6 for wild-
type and OX2R-/- mice, respectively, p = 0.0001) and OX1R-/- mice (n = 6, p = 0.0012), 
and the dose response curve of 2 h NREM sleep in OX2R-/- mice was above those of 
both wild-type (n = 8 and 6 for wild-type and OX2R-/- mice, respectively, p < 0.0001) 
and OX1R-/- mice (n = 6, p = 0.0011) (Fig. 2A, B). In addition, the latency to NREM 
sleep after orexin-A administration was significantly shorter than that in wild-type (n 
= 8 and 6 for wild-type and OX2R-/- mice, respectively, p < 0.0001) and OX1R-/- mice 
(n = 6, p = 0.0003) (Fig. 2D). Importantly, although the effect was smaller than 
observed in the other genotypes, the fact that orexin-A administration increased 
wakefulness in OX2R-/- mice implies that activation of OX1R has wakefulness-
promoting effects. 
Thus, activation of either of the two orexin receptors was sufficient to increase 
wakefulness, but to a degree significantly less than that with simultaneous activation 
of both receptors, suggesting that both OX1R and OX2R mediate the wakefulness-
promoting and NREM sleep-suppressing effects of ICV orexin-A administration. We 
also noted that the contributions of OX2R to these effects were substantially greater 
than those of OX1R. 
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Both OX1R and OX2R are similarly involved in orexin-A-mediated REM sleep 
regulation 
As previously reported, orexin-A administration in wild-type mice potently 
suppressed REM sleep in a dose-dependent manner (n = 8, p < 0.0001) (Figs. 1E, 2C, 
E). REM sleep suppression lasted for 3 h (3 nmol and 1 nmol orexin-A) or for 2 h (0.3 
nmol orexin-A) after administration in wild-type mice (Fig. 1E). 
In both OX1R-/-and OX2R-/- mice, the effects of orexin-A on REM sleep 
suppression dissipated more rapidly than in wild-type mice. In OX1R-/-mice, the lower 
doses of orexin-A (0.3 and 1 nmol) suppressed REM sleep for 1 and 2 h after 
administration, respectively (Fig. 1F). In OX2R-/- mice, REM sleep suppression lasted 
for only 2 h at all doses examined (Fig. 1G). Although the amount of REM sleep in 
the first 3 h after administration was not significantly different among the three 
different genotypes (p = 0.2835 for wild-type vs OX1R-/-mice, p = 0.6582 for wild-
type vs OX2R-/-mice, p = 0.5677 for OX1R-/- vs OX2R-/-mice) (Fig. 2C), the latency to 
REM sleep after administration was slightly shorter in OX1R-/- (n = 6, p = 0.0308) and 
OX2R-/- mice (n = 6, p = 0.0004) than in wild-type mice (n = 8)(Fig. 2E). The latency 
to REM sleep was not different between OX1R-/- and OX2R-/- mice (p = 0.3270). Thus, 
REM sleep suppression following orexin-A administration was slightly and similarly 
attenuated in OX1R-/- and OX2R-/- mice when compared with wild-type mice. These 
results suggest that both OX1R and OX2R mediate REM sleep suppression with 
similar efficacy through different and redundant pathways. 
Since REM sleep episodes are only observed after a prolonged period of 
NREM sleep in normal mammals, it can be speculated that suppression of REM sleep 
by orexin-A administration may occur secondary to suppression of NREM sleep. If 
REM sleep suppression by orexin-A resulted solely from indirect effects of NREM 
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sleep suppression, and orexin-A had no influence on transitions from NREM to REM 
sleep, the emergence of REM sleep episodes would likely depend simply on the 
amount of preceding NREM sleep. After orexin-A administration, OX2R-/- mice spent 
significantly longer in NREM sleep than did OX1R-/-, whereas OX1R-/- and OX2R-/- 
mice spent similar durations in REM sleep (Figs. 1B, C, 2). Thus, in addition to the 
indirect effects, ICV-administered orexin-A is likely to suppress transitions from 
NREM sleep to REM sleep directly. In OX2R-/- mice, furthermore, 1 and 3 nmol 
orexin-A administration suppressed NREM sleep to a similar degree, but orexin-A 
suppressed REM sleep more potently at 3 nmol than 1 nmol (Fig. 3A-C, n = 6, p = 
0.0252 for C). Consistently, latency to REM sleep was not correlated with latency to 
NREM sleep after administration of 1 or 3 nmol of orexin-A in OX2R-/- mice (r = -
0.0407, p = 0.9001), but these parameters were highly correlated in OX1R-/- mice (r = 
0.8332, p < 0.0001) (Fig. 3D). These results suggest that the orexin-A-mediated 
inhibition of REM sleep through OX2R is largely dependent on inhibition of the 
preceding NREM sleep, but that the orexin-A-mediated REM sleep inhibition through 
OX1R may involve a mechanism independent of the effect on NREM sleep. These 
observations again indicate the existence of independent pathways that regulate 
NREM and REM sleep by orexin-A, and further implicate OX1R in the gating of 
NREM/REM sleep transitions. 
 
Differential expression of orexin receptors in neurons with specific 
neurotransmitter identities in nuclei implicated in sleep/wake regulation 
To further understand the molecular basis underlying differential roles of 
orexin receptors in sleep/wakefulness, we next examined their mRNA expression in 
neurons implicated in sleep/wakefulness regulation. We first compared expression 
Mieda et al. – Page 13 
 13
patterns of OX1R and OX2R mRNA in wild-type, OX1R-/- and OX2R-/- mice by in situ 
hybridization. In wild-type mice, consistent with previous studies (Trivedi et al., 
1998; Marcus et al., 2001), the tuberomammillary nucleus (TMN) abundantly 
expressed OX2R (Fig. 4A), and the locus coeruleus (LC) predominantly expressed 
OX1R (Fig. 4B). In the laterodorsal tegmental nucleus (LDT) and pedunculopontine 
tegmental nucleus (PPT), many OX1R-positive cells and fewer OX2R-positive cells 
with a scattered distribution were observed (Fig. 4D, data not shown). In the dorsal 
and median raphe nuclei (DR and MnR), OX1R and OX2R mRNA showed intense 
labeling with similar spatial patterns (Fig. 4C, data not shown). These distributions of 
OX1R and OX2R mRNA were essentially unchanged in mice lacking the other subtype 
of orexin receptor (Fig. 4A-D), suggesting that genetic deletion of one subtype does 
not affect the spatial expression pattern of the remaining subtype. Importantly, no 
significant signal of OX1R and OX2R was detected in OX1R-/- and OX2R-/- mice, 
respectively, confirming specificity of the riboprobes used in this study. 
Monoaminergic (i.e., histaminergic, noradrenergic, and serotonergic) and 
cholinergic neurons in these nuclei have been considered critical for 
sleep/wakefulness regulation (Pace-Schott and Hobson, 2002; Sakurai, 2007). 
However, the expression patterns of orexin receptors in these neurochemically-
defined cells have remained uncertain. Thus, we next performed double in situ 
hybridization to elucidate histologically the subtype of orexin receptors expressed in 
these neurons, using vesicular monoamine transporter 2 (VMAT2) and vesicular 
acetylcholine transporter (VAChT) as molecular markers for monoaminergic and 
cholinergic neurons, respectively (Erickson et al., 1992; Roghani et al., 1994). In 
addition, we also examined co-expression of orexin receptor mRNA and a 
GABAergic marker glutamic acid decarboxylase 1 (Gad1) mRNA in these 
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monoaminergic and cholinergic nuclei (Huang et al., 1990), in view of the possible 
importance of GABAergic interneurons in their functions. 
In the TMN (Fig. 5A), we found many cells stained singly in orange (VMAT2) 
when sections were hybridized to OX1R and VMAT2 probes (top panel). In contrast, 
when hybridized to OX2R and VMAT2 probes (bottom panel), we observed many cells 
doubly stained in blue (OX2R) and orange (VMAT2) but no cell singly stained in 
orange. These results suggested that VMAT2-positive histaminergic neurons did not 
express a detectable level of OX1R mRNA, while OX2R mRNA was co-localized in all 
VMAT2-positive neurons. Notably, we detected Gad1 mRNA in virtually all OX2R-
expressing TMN neurons, suggesting that histaminergic neurons are also GABAergic 
(Fig. 6A). In addition, we found a few VMAT2-negative/Gad1-negative cells 
expressing OX1R mRNA in the same area. 
In the DR (Fig. 5B) and MnR (data not shown), we detected both OX1R and 
OX2R mRNA in approximately 90% of VMAT2-positive serotonergic neurons (DR: 
87.4% and 89.5%, MnR: 96.6% and 92.2% for OX1R and OX2R, respectively), 
suggesting that the majority of serotonergic neurons in these areas express both OX1R 
and OX2R. Many VMAT2-negative non-serotonergic cells in the DR/MnR also 
expressed OX1R or OX2R mRNA. At least some populations of these cells were likely 
to be GABAergic, since a population of Gad1-positive cells demonstrated detectable 
OX1R or OX2R mRNA (Fig. 6B). We could not conclude whether a single population 
of GABAergic neurons expressed both receptors or different populations expressed 
either OX1R or OX2R. 
In the LC (Fig. 5C), all VMAT2-positive noradrenergic neurons exhibited 
intense OX1R expression, whereas OX2R mRNA was exclusively detected in VMAT2-
negative non-noradrenergic neurons. Only some of these OX2R-expressing cells 
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exhibited Gad1 expression, leaving the remaining cells neurochemically unidentified 
(Fig. 6C). 
In the LDT (Fig. 5D) and PPT (data not shown), all VAChT-positive 
cholinergic neurons expressed OX1R but not OX2R mRNA, but many OX1R-positive 
and/or OX2R-positive non-cholinergic neurons were intermingled with cholinergic 
neurons in the area. Gad1 mRNA staining further revealed that OX1R- or OX2R-
expressing cells included both GABAergic and non-GABAergic cells (Fig. 6D). A 
previous study showed that approximately 50% of ChAT immunoreactive neurons in 
the LDT/PPT also contained GABA (Jia et al., 2003), and our double in situ 
hybridization using VAChT and Gad1 probes confirmed at least the existence of such 
cholinergic/GABAergic neurons (data not shown). Thus, in the LDT/PPT, these 
results suggest that: (i) OX1R mRNA is expressed in all cholinergic neurons and 
possibly in GABAergic and neurochemically-unidentified neurons, and (ii) OX2R 
mRNA is expressed in GABAergic and neurochemically unidentified neurons but not 
in cholinergic neurons. Whether both OX1R and OX2R are expressed in the same 
populations of GABAergic or unidentified neurons remains unknown. 
This differential expression of OX1R and OX2R is summarized in Figure 7. 
 
DISCUSSION 
In the present study, we compared the contribution of OX1R and OX2R to the effects 
of ICV orexin-A administration on sleep and wakefulness using mice lacking either 
OX1R or OX2R.    We administered orexin-A, the dual OX1R/OX2R agonist, in all 
mice. Furthermore, we used knockout mice to assure specific and complete deletion 
of orexin receptor genes.  Hence our strategy eliminated confounding factors that 
could affect results from studies that use subtype-selective orexin agonists and/or 
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antagonists, such as specificity, potency, efficacy, occupancy, and stability of the 
administered drugs. In addition, the current lack of availability of an OX1R-selective 
agonist supports our strategy. It is possible that the lack of one receptor subtype might 
be compensated by enhanced expression of the other subtype. However, we found that 
genetic deletion of OX1R or OX2R did not result in an overt change in the distribution 
of the other subtype mRNA (Fig. 4). However, whether the intensity of expression of 
the other receptor is altered remains unknown. 
In this study, we demonstrated that activation of OX2R promotes wakefulness 
and suppresses NREM sleep with substantially higher efficacy than that of OX1R. In 
contrast, both OX1R and OX2R appear to be involved in the suppression of REM 
sleep by orexin-A administration to a similar degree. These findings are consistent 
with the conclusion derived from behavioral studies and baseline sleep/wakefulness 
recordings of OX1R-/- and OX2R-/- mice: the normal regulation of wakefulness/NREM 
sleep transitions depend critically on OX2R, but the profound dysregulation of REM 
sleep control unique to narcolepsy-cataplexy syndromes emerges from loss of 
signaling through both OX1R and OX2R (Willie et al., 2003; Sakurai, 2007). A 
previous pharmacological study using OX1R- and OX2R-selective antagonists in rats 
also demonstrated a principal role of OX2R in suppression of NREM sleep (Dugovic 
et al., 2009). Furthermore, ICV administration of an OX2R-selective agonist 
[Ala11]orexin-B in rats was sufficient to promote wakefulness and suppress NREM 
and REM sleep (Akanmu and Honda, 2005). 
Histaminergic neurons in the TMN are believed to play an important role in 
the wake-promoting effect of orexin, since the effects of ICV orexin-A administration 
are markedly attenuated by the histamine H1 receptor (H1R) antagonist pyrilamine, 
and are absent in H1R-/- mice (Huang et al., 2001; Yamanaka et al., 2002). The TMN 
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abundantly expresses OX2R, supporting a critical contribution of TMN histaminergic 
neurons (Marcus et al., 2001; Yamanaka et al., 2002). Here, and in agreement with the 
previous studies, we showed marked attenuation of orexin-A-induced wakefulness in 
OX2R-/- mice. Additionally, we demonstrated expression of OX2R mRNA in almost all 
TMN histaminergic neurons, which is consistent with a previous 
immunohistochemical study (Yamanaka et al., 2002). Interestingly, our results 
suggested co-expression of histaminergic and GABAergic molecular markers with 
OX2R in the TMN, consistent with previous studies showing that TMN histaminergic 
neurons contain GABA (Ericson et al., 1991; Airaksinen et al., 1992). Despite dense 
histaminergic innervation to the ventrolateral preoptic area (VLPO) from TMN, 
histamine reportedly has no effect on sleep-promoting neurons of this area, which is 
in notable contrast to the inhibitory effects of noradrenaline, serotonin, and 
acetylcholine (Gallopin et al., 2000; Chou et al., 2002). In addition, histidine 
decarboxylase-/- and H1R-/- mice show mild or subtle phenotypes concerning 
sleep/wakefulness regulation under baseline conditions, clearly contrasting with 
OX2R-/- mice, which show marked abnormalities in sleep and wakefulness (Parmentier 
et al., 2002; Willie et al., 2003; Huang et al., 2006; Hondo et al., 2010). Furthermore, 
OX1R-/-;H1R-/- mice also show no detectable abnormality in sleep/wakefulness states 
(Hondo et al., 2010). Thus, GABAergic transmission by TMN histaminergic neurons, 
driven by the OX2R (Willie et al., 2003), may play a critical role, including 
suppression of sleep-promoting neurons in the VLPO. 
However, orexin-A administration in OX2R-/- mice still caused an increase in 
wakefulness. Thus, OX1R-expressing neurons may also play a role in the effects of 
orexin-A. Consistent with this thesis, fragmentation of wakefulness in OX2R-/- mice is 
milder than that in OX1R-/-;OX2R-/- mice (Sakurai, 2007). In addition, ICV 
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administration of an OX2R-selective agonist [Ala11]orexin-B seemed less effective 
when compared with orexin-A (Akanmu and Honda, 2005). However, ICV 
administration of orexin-A in OX2R-deficient dogs has been reported to have no effect 
on time spent in wakefulness (Fujiki et al., 2003). This discrepancy between the 
studies with OX2R-defficient mice and dogs may be explained by differences in doses, 
time windows of analyses, numbers of animals examined, and species (Willie et al., 
2003). 
LC noradrenergic neurons, which abundantly express OX1R, are one of the 
candidate systems to mediate the arousal effect mediated by OX1R. Indeed, 
microinjection of orexin-A into the LC increases wakefulness (Bourgin et al., 2000). 
Other regions that could mediate OX1R-induced arousal effects include cholinergic 
neurons in the LDT/PPT, and serotonergic neurons in the raphe nuclei, both of which 
are thought to be critically involved in the regulation of sleep/wakefulness states 
(Pace-Schott and Hobson, 2002; Sakurai, 2007). Redundant expression of both OX1R 
and OX2R mRNA was reported in raphe nuclei (Marcus et al., 2001). We showed that 
most serotonergic neurons in the DR and MnR are positive for OX1R and/or OX2R 
mRNA, which is in accordance with a previous single-cell PCR study (Brown et al., 
2001). In addition to the direct excitatory effects, orexins act indirectly to activate 
local inhibitory GABAergic input to serotonergic neurons (Liu et al., 2002). This is 
consistent with our present finding of expression of orexin receptors in GABAergic 
neurons of the DR/MnR. 
In contrast to the regulation of wakefulness/NREM sleep transitions, orexin-A 
suppressed REM sleep similarly in OX1R-/- and OX2R-/- mice. Considering that OX2R-/- 
mice spent longer in NREM sleep than did OX1R-/- mice after orexin-A administration, 
activation of OX1R may more potently suppress REM sleep than does OX2R. Our 
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observations further suggest that orexin-A directly suppresses transitions from NREM 
sleep to REM sleep, and that activation of OX1R is sufficient for this effect. OX2R 
activation may suppress REM sleep directly at the transition from NREM sleep and/or 
indirectly at the transition from wakefulness to NREM sleep. Paradoxically, in vivo 
single unit recordings revealed that orexin neurons discharge during active waking, 
have decreased firing rates during quiet waking, and virtually cease firing during both 
REM and NREM sleep (Lee et al., 2005; Mileykovskiy et al., 2005; Takahashi et al., 
2008). It is possible that extremely low activity of orexin neurons or residual orexin 
neuropeptides in the extracellular fluid during NREM sleep after wakefulness may 
prevent the induction of REM sleep. 
Previous findings also suggest gating of NREM/REM sleep transitions by 
orexin-A. First, local administration of orexin-A into the LC of rats, which abundantly 
expresses OX1R, suppressed REM sleep without significant alteration in NREM sleep 
(Bourgin et al., 2000). Second, systemic administration of a selective OX1R 
antagonist SB-334867 reversed REM sleep suppression caused by ICV orexin-A 
administration at a dose which produced no significant change in NREM sleep (Smith 
et al., 2003). In addition, deficiency in this type of REM sleep regulation may underlie 
the unproportionally large increase in REM sleep time when compared with the 
increase in NREM sleep in narcoleptic orexin-/- and OX1R-/-;OX2R-/- mice (Chemelli et 
al., 1999; Sakurai, 2007). These observations suggest that orexin-A-mediated 
suppression of REM sleep might primarily be mediated by noradrenergic neurons in 
the LC, which send collateral projections to cholinergic neurons in the LDT/PPT. 
Differential expression of orexin receptors in cholinergic and GABAergic 
neurons of the LDT/PPT is also intriguing. Exclusive expression of OX1R in 
cholinergic neurons is also supported by a previous study demonstrating that the 
Mieda et al. – Page 20 
 20
excitatory effects of orexin-A on PPT cholinergic neurons were suppressed by a 
selective OX1R antagonist SB-334867 (Kim et al., 2009). Cholinergic neurons in 
these areas include those that are active during wakefulness and REM sleep (W/REM-
on neurons) and those that are specifically active during REM sleep (REM-on 
neurons) (Pace-Schott and Hobson, 2002; Sakurai, 2007). The latter population is 
likely to play a critical role in REM sleep-related physiological phenomena, including 
muscle atonia. Nevertheless, orexin-A excites both cholinergic and non-cholinergic 
neurons of the LDT in slice preparations (Burlet et al., 2002). Furthermore, orexin-A 
microinjection in the cat LDT increases wakefulness and reduces REM sleep (Xi et al., 
2001). A recent study suggested that GABAergic neurons in the PPT mediate 
suppression of REM sleep and muscle atonia following local injection of orexin-A 
into this area (Takakusaki et al., 2005). Taken together, these results indicate that in 
the LDT/PPT, orexin may activate W/REM-on cholinergic neurons through OX1R to 
facilitate wakefulness. Simultaneously, orexin might activate GABAergic 
interneurons to inhibit REM-on cholinergic neurons in these nuclei. Additionally, 
orexinergic activation of wake-active noradrenergic and serotonergic neurons in the 
LC and raphe nuclei is likely to counteract activation of REM-on cholinergic neurons 
in the LDT/PPT during wakefulness (Pace-Schott and Hobson, 2002; Sakurai, 2007). 
This is consistent with the fact that tricyclic antidepressants and serotonin-specific 
reuptake inhibitors are effective for treating cataplexy in narcoleptic patients. 
In conclusion, our findings highlight the complex redundant and/or 
compensatory pathways involving OX1R and OX2R mediating the effects of orexin-A 
administration on sleep/wakefulness regulation (Fig. 7). Thus, dual agonists for both 
OX1R and OX2R might have greater potential than subtype-selective agonists as novel 
treatments for narcolepsy and other states of hypersomnolence. 
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FIGURE LEGENDS 
Figure 1. Attenuated effects of ICV orexin-A administration on sleep/wakefulness 
states in orexin receptor-deficient mice. Hourly plots of time spent awake (A-D) and 
in REM sleep (E-H) after ICV orexin-A administration in wild-type (WT) (A and E), 
OX1R-/- (B and F), OX2R-/- (C and G), and OX1R-/-;OX2R-/- mice (D and H). Since 
hourly distributions of NREM sleep were essentially mirrored by those of 
wakefulness in all genotypes examined, those for NREM sleep are not shown. *, p < 
0.05 for 0 nmol vs. 0.3 nmol; +, p < 0.05 for 0 nmol vs. 1 nmol; #, p < 0.05 for 0 nmol 
vs. 3 nmol; one-way repeated-measures ANOVA and Tukey post-hoc tests. Values are 
mean ± S.E. (n = 8 for wild-type mice, n = 6 for OX1R-/- and OX2R-/- mice, n = 3 for 
OX1R-/-;OX2R-/- mice). 
 
Figure 2. Differential effects on sleep/wakefulness states following activation of 
OX1R and OX2R. Dose responses of the effect of ICV orexin-A on time spent awake 
(A), in NREM sleep (B), and in REM sleep (C) within 2 h (A, B) or 3 h (C) following 
administration. Analysis of REM sleep over 3 h is shown here (C) since the effects on 
REM sleep persisted longer than those on wakefulness and NREM sleep. Note that a 
similar analysis of REM sleep over a 2 h period leads to the same conclusion. Dose 
responses of the effect of ICV orexin-A on latency to the first episode of NREM sleep 
(D) and REM sleep (E) following administration. *, +, #, p < 0.05 for effect of dose in 
each genotype (*), effect of genotype as compared to wild-type mice (+), and 
interaction of dose and genotype as compared to WT mice (#); “1”, “2”, “D” above 
curves, p < 0.05 for WT vs OX1R-/- (“1”), WT vs OX2R-/- (“2”), and WT vs OX1R-/-
;OX2R-/- mice (“D”) at each dose, by two-way repeated-measures ANOVA. Values are 
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mean ± S.E. (n = 8 for wild-type mice, n = 6 for OX1R-/- and OX2R-/- mice, n = 3 for 
OX1R-/-;OX2R-/- mice). 
 
Figure 3. Orexin-A directly suppresses transitions from NREM sleep to REM sleep. 
Cumulative time spent in NREM (A) and REM sleep (B) following ICV orexin-A in 
OX2R-/- mice. +, p < 0.05 for effect of dose as compared to 3 nmol administration, by 
two-way repeated-measures ANOVA. (C) Percent of time spent in NREM or REM 
sleep within 4 h following 1 or 3 nmol orexin-A administration relative to vehicle 
administration in OX2R-/- mice. *, +, #, p < 0.05 for effect of dose in each vigilance 
state (*), effect of vigilance state at each dose (+), and interaction of dose and 
vigilance state (#), by two-way repeated-measures ANOVA. (D) A scatter plot of 
latencies to NREM sleep and REM sleep after administration of 1 nmol or 3 nmol 
orexin-A. Pearson’s correlation coefficients (r) and p-values for each genotype are 
shown. 
 
Figure 4. Similar distributions of OX1R and OX2R mRNA in wake-active nuclei of 
wild-type, OX1R-/- and OX2R-/- mice. Coronal brain sections containing TMN (A), LC 
(B), DR (C), and LDT (D) from wild-type, OX1R-/- and OX2R-/- mice were hybridized 
in situ to an OX1R or OX2R antisense probe. 3v, third ventricle; 4v, fourth ventricle, 
Aq, aqueduct. Scale bar, 100 µm. 
 
Figure 5. Differential distribution of OX1R and OX2R mRNA in monoaminergic and 
cholinergic neurons implicated in regulation of wakefulness. Coronal brain sections 
containing TMN (A), DR (B), LC (C), and LDT (D) from wild-type mice were 
hybridized in situ to an OX1R (top) or OX2R (bottom) antisense probe (blue stain) 
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combined with either a monoaminergic marker VMAT2 (A, histaminergic; B, 
serotonergic; C, noradrenergic neurons) or cholinergic marker VAChT (D) antisense 
probe (orange stain). The locations and sizes of magnified images (right) are shown 
by white rectangles in the low-power images (left). Representative cells stained blue, 
orange, or both are indicated by blue, orange, and green arrowheads, respectively. 
Enlargements of some of these representative cells are shown in insets of the left 
panels. 3v, third ventricle; 4v, fourth ventricle, Aq, aqueduct. Scale bars shown in A, 
100 µm and 50 µm for low- and high-power images, respectively. 
 
Figure 6. Differential distributions of OX1R and OX2R mRNA in GABAergic neurons 
in wake-promoting nuclei. Coronal brain sections containing TMN (A), DR (B), LC 
(C), and LDT (D) from WT mice were hybridized in situ to an OX1R (top) or OX2R 
(bottom) antisense probe (blue stain) combined with a GABAergic marker Gad1 
(orange stain). The locations and sizes of magnified images (right) are shown by 
white rectangles in the low-power images (left). Representative cells stained blue, 
orange, or both are indicated by blue, orange, green arrowheads, respectively. 
Enlargements of some of these representative cells are shown in insets of the left 
panels. 3v, third ventricle; 4v, fourth ventricle, Aq, aqueduct. Scale bars shown in A, 
100 µm and 50 µm for low- and high-power images, respectively. 
 
Figure 7. Schematic illustration of presumed pathways underlying orexin actions on 
NREM and REM sleep. Orexins activate histaminergic (His)/GABAergic (GA), 
serotonergic (5HT), noradrenergic (NA), and cholinergic (ACh) neurons, as well as 
GABAergic and neurochemically unidentified (not shown in this figure for simplicity) 
putative interneurons, in wake-promoting nuclei, including the TMN, DR/MnR, 
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LDT/PPT, and LC. These neurons differentially express OX1R and/or OX2R, and 
regulate wakefulness/NREM sleep and NREM/REM sleep transitions. OX1R and 
OX2R may be expressed in the same populations of GABAergic neurons, as shown in 
the figure, or may be expressed in distinct populations of these neurons in each area. 
Wake/REM-on cholinergic neurons (ACh/W) are likely to suppress NREM sleep but 
REM-on cholinergic neurons (ACh/R) are likely to induce REM sleep. Wake-active 
serotonergic and noradrenergic neurons in the DR/MnR and LC, respectively, 
counteract activation of REM-on cholinergic neurons in the LDT/PPT, as well as 
REM-on neurons in the brainstem reticular formation (Sakurai et al., 1998; Pace-
Schott and Hobson, 2002). Previous reports have suggested contributions of 
GABAergic interneurons inhibiting PPT cholinergic and raphe serotonergic neurons 
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